Imagine your knee has a built-in shock absorber called the meniscus. When this part wears out or is removed, the knee joint grinds down, causing severe pain. This project creates a high-tech replacement part made of special plastics that mimics the natural cushion, acting like a new shock breaker for the leg.
Young patients with lateral meniscus damage face a 13-year treatment gap where they must rely on painkillers until they are old enough for a total knee replacement. This results in massive healthcare costs and lost productivity.
A lateral meniscus prosthesis called Trammpolin made of two biocompatible polymers, including a fixation method using ligament tape.
If you are a medical device manufacturer dealing with the lack of options for young knee patients — this project developed the Trammpolin prosthesis that restores mobility and postpones total knee replacement. It uses a minimally invasive arthroscopic approach to fill a treatment gap affecting 350,000 patients.
If you are a clinic dealing with high patient demand for knee osteoarthritis treatments — this project developed a flexible implant that reduces peak pressure on cartilage. This allows you to offer a solution to the 70,000 new lateral patients entering the pool every year.
If you are an insurer dealing with the economic burden of lateral KOA costing €40K-€79k per patient — this project developed a durable prosthesis that reduces medication dependency and absenteeism. This lowers the long-term healthcare costs associated with chronic knee disability.
The economic burden of lateral knee osteoarthritis is estimated between €40K and €79k per patient due to medical costs, absenteeism, and disability.
The project is currently optimizing design and conducting a First In Human-study to achieve CE-marking for a planned market entry in 2026.
Based on available project data, the technology has already received the Breakthrough Device Designation from the US FDA in 2020 for the medial version.
The project must obtain CE-marking and perform a health economics analysis to secure reimbursement from medical systems.
The target for successful market entry is 2026.
The project is led by a single SME, ATRO Medical BV from the Netherlands. This 100% industry-led structure indicates a strong commercial drive and a streamlined decision-making process, focusing on rapid transition from lab testing to CE-marking and market entry.
Contact ATRO Medical BV in the Netherlands regarding the Trammpolin lateral prosthesis.
Contact us to explore licensing opportunities for biocompatible polymer implants.
